Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Intravitreal OTX-TKI in nAMD
NCT07516132Phase 3Recruiting
- Sponsor
- Ocular Therapeutix
- Start
- Apr 2026
- Primary completion
- Aug 2030
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of axitinib in neovascular age-related macular degeneration (NVAMD), sponsored by Ocular Therapeutix. Started Apr 2026; status: recruiting.
02
Drugs
axitinib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07516132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07516132.